🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    The George Institute

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  2. Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    2 trials

  3. Allogeneic MSC (AlloMSC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Systemic Lupus Erythematosus

    phase 2 mab active

    1 trial

  4. Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  5. Allogeneic NK Cells

    Artiva Biotherapeutics

    Refractory Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  6. Allogenic expanded Natural Killer Cells (AlloNK1)

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 mab active

    1 trial

  7. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Non-small Cell Stage IV

    phase 2 small molecule active

    1 trial

  8. Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  9. AloCelyvir

    The George Institute

    mEtastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  10. Alogabat

    Hoffmann-La Roche

    Angelman Syndrome

    phase 2 small molecule completed

    1 trial

  11. Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  12. Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  13. Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

    The George Institute

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  14. Amimox 500 mg filmdragerade tabletter, Kåvepenin 800 mg filmdragerade tabletter

    The George Institute

    Need of Oral bone augmentation

    phase 2 small molecule active

    1 trial

  15. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  16. Anrotinib plus Tirelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  17. Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  18. Anti-PD-1 antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Anti-PD-1 antibody drug named Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IV HCC

    phase 2 small molecule active

    1 trial

  20. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial

  21. Antithymocyte globulin (ATG)

    Ultragenyx UK Limited

    Myelodysplastic Syndrome

    phase 2 small molecule active

    1 trial

  22. Anvumetostat

    Amgen

    Advanced MTAP-null Solid Tumors

    phase 2 small molecule active

    1 trial

  23. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Esophageal Squamous Carcinoma

    phase 2 small molecule active

    1 trial

  24. Apatinib

    Hospital Authority, Hong Kong

    Soft Tissue Sarcoma, Adult, Stage II

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources